The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Oral hypomethylating agents in CMML: clinical evidence and emerging combinations
Daniel Wiseman, MD, University of Manchester, Manchester, UK, discusses the evolving role of oral hypomethylating agents (HMAs) in chronic myelomonocytic leukemia (CMML). Dr Wiseman highlights findings from the Phase II AMMO trial evaluating oral decitabine/cedazuridine (ASTX727), alongside emerging data on oral azacitidine/cedazuridine (ASTX030), exploring improvements in treatment efficacy, tolerability, and patient convenience. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
